Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brooks Jackson

Showing results (131-140 of 134) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 134 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Microbiology Spectrum|January 26, 2022
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike GlycoproteinHanora A Van Ert, Dana W Bohan, Kai Rogers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2013
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trialMary Glenn Fowler, Hoosen Coovadia, Casey M Herron, et al.
Lancet (London, England)|July 29, 2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials, Abubaker Bedri, Berhanu Gudetta, et al.
Pageof 14

Showing results (131-140 of 134) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 134 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 8, 2015
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058David S Metzger, Deborah Donnell, David D Celentano, et al.
Microbiology Spectrum|January 26, 2022
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike GlycoproteinHanora A Van Ert, Dana W Bohan, Kai Rogers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2013
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trialMary Glenn Fowler, Hoosen Coovadia, Casey M Herron, et al.
Lancet (London, England)|July 29, 2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials, Abubaker Bedri, Berhanu Gudetta, et al.
Pageof 14